COMPANY

Adaptilens

Profile checked Oct 10, 2026

Keywords: Aphakia Cataract

Raises and deals from press releases

Raise Series A · $17.5M · announced Apr 29, 2024 Company release ↗
Source quote
- Apr 29, 2024 · Company release ↗
  “BOSTON, April 29, 2024 /PRNewswire/ — Adaptilens, Inc., a pre-clinical company dedicated to transforming the standard of care for cataract surgery, today announced the closing of a Series A financing round of $17.5 million led by Perceptive Xontogeny Venture Funds (PXV Funds)”

Raises announced in these releases: $17.5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Apr 29, 2024 Raise Series A · $17.5M source ↗
2026-09 Trial start Not phased (device or behavioral study): Clinical Evaluation of the Adaptilens Accommodating IOL source ↗

2030-12 (ESTIMATED) · Not phased · Clinical Evaluation of the Adaptilens Accommodating IOL · NCT07607860

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07607860	Clinical Evaluation of the Adaptilens Accommodating IOL	Not phased (device or behavioral study)	Not yet recruiting	2026-09	2030-12 (estimated)